Table 1 Summary of patient characteristics

From: Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome

Diagnosis

No. of patients (%)

AML

29 (74)

MDS

10 (26)

Age (years)

 Median

69

 Range

36–82

 ⩾65

30 (75)

 ⩾75

11 (28)

Sex

 Male

26

 Female

13

WBC at diagnosis x 10 9 /l

 Median

4.4

 Range

0.8–105

ECOG PS

 0–1

34 (87)

 2

5 (13)

AML (WHO subtype)

 AML with MRC

17 (59)

 AML NOS

10 (34)

 Therapy related AML

2 (7)

AML karyotype

 Intermediate

17 (59)

 Adverse

12 (41)

MDS (IPSS Score)

 Intermediate-2

7 (70)

 High

3 (30)

  1. Abbreviations: AML, acute myeloid leukemia; ECOG PS, Eastern Cooperative Oncology Group Performance Score; IPSS, International Prognostic Scoring System; MDS, myelodysplastic syndrome; MRC, myelodysplasia-related changes based on the presence of either (1) previously documented MDS or MDS/myeloproliferative neoplasm (MPN), (2) specific myelodysplasia-related cytogenetic abnormalities, or (3) dysplasia in 50% or more of the cells in 2 or more myeloid lineages; NOS, not otherwise specified; WBC, white blood cell count; WHO, World Health Organisation.
Back to article page